SSCI tackle poor drug solubility
SSCI, the Indiana-based contract laboratory specialising in solid-state chemistry, has launched a new service to address the problem of poor aqueous solubility in the development of new drug products that involves the use of amorphous materials.
SSCI, the Indiana-based contract laboratory specialising in solid-state chemistry, has launched a new service to address the problem of poor aqueous solubility in the development of new drug products that involves the use of amorphous materials.
Amorphous materials are generally much more soluble than their crystalline counterparts, and can often be formulated to be physically and chemically stable throughout their shelf life, SSCI says.
The laboratory has developed several techniques to search for and stabilise amorphous forms. One of the techniques involves the creation of a stabilised nano-suspension of the Active Pharmaceutical Ingredient (API) within a guest solid matrix. Control of the small API particle size can give control over the solubility.
A combination of total scattering x-ray diffraction methods provides a robust method for characterisation of the solid-state form of the API within the nanoparticles.
The same methodology can determine if the nanoparticles have become miscible with the matrix forming a solid solution, or if the API has begun to phase separate, giving larger particles.